Literature DB >> 23165303

Resistant hypertension--its identification and epidemiology.

Pantelis A Sarafidis1, Panagiotis Georgianos, George L Bakris.   

Abstract

Resistant hypertension is currently defined as the failure to achieve a goal blood pressure <140/90 mmHg in patients who are compliant with maximal tolerated doses of a minimum of three antihypertensive drugs, one of which must be a diuretic. The increasing prevalence of obesity and hypertension in the general population mean that this disorder has gained attention in the past decade. In the past 2 years, large-scale population-based studies such as the US National Health and Nutrition Examination Survey (NHANES) have specifically examined the prevalence and incidence of resistant hypertension, and associated risk factors. The findings suggest the prevalence of resistant hypertension is 8-12% of adult patients with hypertension (6-9 million people). The increasing prevalence of resistant hypertension contrasts with the improvement in blood pressure control rates during the same period. Studies also show that patients with resistant hypertension aged >55 years, of black ethnicity, with high BMI, diabetes or chronic kidney disease have an increased risk of cardiovascular events compared to nonresistant hypertensive patients. Analyses that exclude the effects of white-coat hypertension and pseudoresistant hypertension are also needed to clarify the epidemiology of true resistant hypertension.

Entities:  

Mesh:

Year:  2012        PMID: 23165303     DOI: 10.1038/nrneph.2012.260

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  47 in total

Review 1.  Resistant hypertension.

Authors:  Norman M Kaplan
Journal:  J Hypertens       Date:  2005-08       Impact factor: 4.844

2.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

3.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

4.  Is resistant hypertension really resistant?

Authors:  M A Brown; M L Buddle; A Martin
Journal:  Am J Hypertens       Date:  2001-12       Impact factor: 2.689

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension.

Authors:  Gil F Salles; Claudia R L Cardoso; Elizabeth S Muxfeldt
Journal:  Arch Intern Med       Date:  2008-11-24
View more
  60 in total

Review 1.  Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?

Authors:  Antonios A Lazaridis; Pantelis A Sarafidis; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

2.  Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.

Authors:  Peter Hayes; Monica Casey; Liam G Glynn; Gerard J Molloy; Hannah Durand; Eoin O'Brien; Eamon Dolan; John Newell; Andrew W Murphy
Journal:  Br J Gen Pract       Date:  2018-05-08       Impact factor: 5.386

3.  Interventional cardiology: Indications for renal denervation: a balanced approach?

Authors:  George L Bakris
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

Review 4.  Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?

Authors:  Patricia Van der Niepen; Patrick Rossignol; Jean-Philippe Lengelé; Elena Berra; Pantelis Sarafidis; Alexandre Persu
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

5.  Magnetic resonance guided renal denervation using active tracking: first in vivo experience in Swine.

Authors:  F Bönner; S Haberkorn; P Behm; B Schnackenburg; S Krüger; S Weiss; C Meyer; M Kelm; M Neizel-Wittke
Journal:  Int J Cardiovasc Imaging       Date:  2017-09-27       Impact factor: 2.357

Review 6.  The programming of cardiovascular disease.

Authors:  K L Thornburg
Journal:  J Dev Orig Health Dis       Date:  2015-07-15       Impact factor: 2.401

Review 7.  Renal Denervation: Where to Now?

Authors:  Neil J Wimmer; Laura Mauri
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

8.  Is hypertension an autoimmune disease?

Authors:  Jordan S Pober
Journal:  J Clin Invest       Date:  2014-09-17       Impact factor: 14.808

Review 9.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

10.  Management of Resistant Hypertension: Do Not Give Up on Medication.

Authors:  Eric Judd; David A Calhoun
Journal:  Nephrol Self Assess Program       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.